top of page

Latest News

Aug 17, 2023

Neosoma Receives SOC 2 Type II Certification

Neosoma Announced Today That It Has Achieved SOC 2 Type II Compliance

Neosoma Receives SOC 2 Type II Certification

Mar 15, 2023

Neosoma Expands Board of Directors with Debbie Millin and Fred Driscoll

Addition of Two New Board Members Represents Inflection Point for Neosoma, Inc.

Neosoma Expands Board of Directors with Debbie Millin and Fred Driscoll

Feb 24, 2023

Hackensack Meridian Health Partners with Neosoma

Neosoma Announced Today a Strategic Partnership with Hackensack Meridian Health for Innovation in Brain Tumor Treatment and Research

Hackensack Meridian Health Partners with Neosoma

Jan 20, 2023

Neuro-Oncology Advances Publishes About Neosoma's Technology

Neosoma HGG's (NS-HGlio) Technology and Development was Recently Published in Neuro-Oncology Advances

Neuro-Oncology Advances Publishes About Neosoma's Technology

Dec 9, 2022

Neosoma Participates in Big Data Federated Learning Study

UPenn-led study brought together almost 6,500 brain cancer MRIs from 71 sites on 6 continents to study the benefits of federated-learning-based AI on glioblastoma segmentation.

Neosoma Participates in Big Data Federated Learning Study

Nov 17, 2022

AI-Powered Neuro-Oncology Clinical Trials

Neosoma's strategic partnership with Calyx enables faster, more precise tumor assessment in brain cancer clinical trials.

AI-Powered Neuro-Oncology Clinical Trials

Nov 7, 2022

Neosoma Announces Partnership with Nuance Communications

Neosoma Announced Today its AI Solutions Connect to the Nuance Precision Imaging Network

Neosoma Announces Partnership with Nuance Communications

Sep 29, 2022

Neosoma Announces FDA 510(k) Clearance for Neosoma HGG

Neosoma Announced Today It Has Received U.S. Food and Drug Administration (FDA) 510(k) Clearance for Its First AI-Based Neuro-Oncology Software, Neosoma HGG

Neosoma Announces FDA 510(k) Clearance for Neosoma HGG
bottom of page